Acid sphingomyelinase deficiency protects from cisplatin-induced gastrointestinal damage

[1]  Xavier Tekpli,et al.  Cisplatin-induced apoptosis involves membrane fluidification via inhibition of NHE1 in human colon cancer cells. , 2007, Cancer research.

[2]  J. Jaffrezou,et al.  Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. , 2004, Blood.

[3]  E. Solary,et al.  Cisplatin-Induced CD95 Redistribution into Membrane Lipid Rafts of HT29 Human Colon Cancer Cells , 2004, Cancer Research.

[4]  R. Kolesnick,et al.  Raft ceramide in molecular medicine , 2003, Oncogene.

[5]  Y. Naomoto,et al.  Apoptosis in Normal Tissues Induced by Anti-Cancer Drugs , 2003, The Journal of international medical research.

[6]  E. Gulbins,et al.  Ceramide and cell death receptor clustering. , 2002, Biochimica et biophysica acta.

[7]  O. Sansom,et al.  The ability to engage enterocyte apoptosis does not predict long-term crypt survival in p53 and Msh2 deficient mice , 2002, Oncogene.

[8]  Zvi Fuks,et al.  Endothelial Apoptosis as the Primary Lesion Initiating Intestinal Radiation Damage in Mice , 2001, Science.

[9]  John Calvin Reed,et al.  Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine -1-phosphate therapy , 2000, Nature Medicine.

[10]  Z. Fuks,et al.  Radiation-induced apoptosis of endothelial cells in the murine central nervous system: protection by fibroblast growth factor and sphingomyelinase deficiency. , 2000, Cancer research.

[11]  Weiya Ma,et al.  Direct Evidence for an Important Role of Sphingomyelinase in Ultraviolet-induced Activation of c-Jun N-Terminal Kinase* , 1997, The Journal of Biological Chemistry.

[12]  R. Brown,et al.  Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance. , 1996, Molecular pharmacology.

[13]  Seamus J. Martin,et al.  Acid Sphingomyelinase–Deficient Human Lymphoblasts and Mice Are Defective in Radiation-Induced Apoptosis , 1996, Cell.

[14]  D. Perl,et al.  Acid sphingomyelinase deficient mice: a model of types A and B Niemann–Pick disease , 1995, Nature Genetics.

[15]  H. Grunicke,et al.  Cytotoxic and cytostatic effects of antitumor agents induced at the plasma membrane level. , 1992, Pharmacology & therapeutics.

[16]  J. Smyth,et al.  Small intestinal mucosal toxicity of cis-platinum--comparison of toxicity with platinum analogues and dexamethasone. , 1986, British Journal of Cancer.

[17]  P. Loehrer,et al.  Drugs five years later. Cisplatin. , 1984, Annals of internal medicine.

[18]  S. Harrison.  Toxicologic evaluation of cis-diamminedichloroplatinum II in B6D2F1 mice. , 1981, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[19]  S. Crooke,et al.  Antileukemia (L1210) activity and toxicity of cis-dichlorodiammineplatinum(II) analogs. , 1979, Cancer treatment reports.